BioXcel Therapeutics, Inc.
BTAI
$1.85
$0.169.47%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -2.66% | -37.24% | 141.58% | 182.52% | 57.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.66% | -37.24% | 141.58% | 182.52% | 57.98% |
| Cost of Revenue | 16.53% | 128.52% | 138.46% | 788.89% | 7,833.33% |
| Gross Profit | -37.87% | -459.06% | 141.76% | 154.82% | -247.60% |
| SG&A Expenses | -57.37% | -68.44% | -63.47% | -43.78% | -53.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.54% | -68.63% | -66.82% | -51.86% | -61.89% |
| Operating Income | 47.37% | 68.87% | 68.63% | 52.80% | 62.42% |
| Income Before Tax | 51.21% | 72.96% | 84.49% | 49.26% | 59.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 51.21% | 72.96% | 84.49% | 49.26% | 59.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.21% | 72.96% | 84.49% | 49.26% | 59.39% |
| EBIT | 47.37% | 68.87% | 68.63% | 52.80% | 62.42% |
| EBITDA | 47.55% | 68.99% | 68.73% | 52.88% | 62.51% |
| EPS Basic | 70.45% | 81.33% | 88.76% | 52.96% | 61.30% |
| Normalized Basic EPS | 70.54% | 81.97% | 89.92% | 52.96% | 61.30% |
| EPS Diluted | 70.45% | 81.33% | 88.76% | 52.96% | 61.30% |
| Normalized Diluted EPS | 70.54% | 81.97% | 89.92% | 52.96% | 61.30% |
| Average Basic Shares Outstanding | 65.11% | 44.83% | 37.91% | 7.87% | 4.92% |
| Average Diluted Shares Outstanding | 65.11% | 44.83% | 37.91% | 7.87% | 4.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |